| Literature DB >> 28594343 |
Aldo Pourchet1, Aram S Modrek2, Dimitris G Placantonakis3,4,5,6,7, Ian Mohr8,9, Angus C Wilson10,11.
Abstract
Herpes simplex virus 1 (HSV-1) uses latency in peripheral ganglia to persist in its human host, however, recurrent reactivation from this reservoir can cause debilitating and potentially life-threatening disease. Most studies of latency use live-animal infection models, but these are complex, multilayered systems and can be difficult to manipulate. Infection of cultured primary neurons provides a powerful alternative, yielding important insights into host signaling pathways controlling latency. However, small animal models do not recapitulate all aspects of HSV-1 infection in humans and are limited in terms of the available molecular tools. To address this, we have developed a latency model based on human neurons differentiated in culture from an NIH-approved embryonic stem cell line. The resulting neurons are highly permissive for replication of wild-type HSV-1, but establish a non-productive infection state resembling latency when infected at low viral doses in the presence of the antivirals acyclovir and interferon-α. In this state, viral replication and expression of a late viral gene marker are not detected but there is an accumulation of the viral latency-associated transcript (LAT) RNA. After a six-day establishment period, antivirals can be removed and the infected cultures maintained for several weeks. Subsequent treatment with sodium butyrate induces reactivation and production of new infectious virus. Human neurons derived from stem cells provide the appropriate species context to study this exclusively human virus with the potential for more extensive manipulation of the progenitors and access to a wide range of preexisting molecular tools.Entities:
Keywords: HSV-1; alphaherpesvirus; embryonic stem cells; herpes simplex virus; human; latency; primary neurons; reactivation
Year: 2017 PMID: 28594343 PMCID: PMC5488658 DOI: 10.3390/pathogens6020024
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Figure 1In vitro derivation of human neural stem cells by differentiation of the Hes5::GFP human embryonic stem cell line. (A) Schematic showing the multistep neural induction protocol. TGFβi stands for TGF-β receptor I inhibitor (B) Bright field image of human embryonic stem cell (hESC) colonies cultured on mouse embryonic fibroblasts prior to reaching confluence. (C) Bright field image of rosette NSCs derived from dissociated hESC colonies cultured in neural induction media. (D) Phase contrast and indirect immunofluorescence images of NSC cultures grown on poly-l-ornithine/laminin-coated dishes in neural stem cell media and probed with an antibody against nestin, a neural stem cell marker. Nuclei were visualized with DAPI.
Figure 2Neuronal cultures lose expression of the progenitor marker nestin and gain expression of multiple neuronal markers. Neuronal differentiation was monitored by indirect immunofluorescence microscopy using antibodies to (A) nestin, a marker of NSCs, and (B) neuronal markers MAP2A, β-3 tubulin (Tuj1), and doublecortin (DCX). (C) Higher magnification imaging reveals a relatively homogeneous population of neurons expressing MAP2A. Nuclei were detected with DAPI.
Figure 3hESC-derived neurons support productive HSV-1 replication. (A) Schematic showing HSV-1 GFP-Us11 (Patton strain), a recombinant expressing enhanced GFP fused in frame to the N terminus of the true late protein Us11 [52]. (B) Bright field and fluorescent imaging of neurons infected at MOI = 0.001 and imaged by light microscopy after 4 days. The majority of the neurons exhibited obvious cytopathogenic effects and expressed the true-late GFP-Us11 fusion protein indicative of active viral replication. (C) Multi-cycle replication assay. 1 × 105 neurons were infected at either MOI = 0.01 (1 × 103 pfu) or MOI = 3 (3 × 105 pfu). Culture media was collected after a further four days and the yield of infectious virus determined by plaque assay on Vero cells. Values represent the total number of plaque forming units (pfu) per well and graphed as the mean ± SEM.
Figure 4Dose-dependent suppression of productive replication by IFN-α in combination with ACV and low viral inoculum. (A) General infection scheme. Neurons were pretreated with 100 μM ACV and different doses of IFN-α the day before (designated day-1) infection with HSV-1 (day 0). (B–D) Evaluation of infectious dose and IFN-α treatment in the establishment of non-productive infections. Neurons were incubated with HSV-1 GFP-Us11 for 4 h at MOI = 0.001 (B), 0.01 (C), or 0.1 (D). After 4 h the media was replaced with fresh media and repeated every other day. ACV and IFN-α were included in the media as indicated until 6 dpi (‘establishment period’) at which point neurons were cultured in maintenance media lacking antiviral compounds and monitored daily for GFP fluorescence. Graphs show the percentage of GFP negative wells under each condition. (E) Neuron cultures were infected with HSV-1 GFP-Us11 at MOI = 0.01 in presence of ACV and 250 IU/mL IFN-α and RNA was collected at 1, 6, and 12 dpi and analyzed by quantitative reverse transcription PCR (qRT-PCR) using primers to the HSV-1 LAT intron. Values were normalized to host GAPDH mRNA.
Figure 5Reactivation of infected cultures using sodium butyrate. (A) Neurons infected with HSV-1 GFP-Us11 at MOI = 0.01 in presence of 100 μM ACV and 250 IU/mL IFN-α were treated with 5 mM sodium butyrate (NaBu) and monitored for GFP fluorescence. The NaBu was added at either 12 or 22 dpi. The percentage of GFP negative wells is shown. (B) Supernatants were collected at 12 dpi from GFP negative wells [GFP−] or NaBu treated and maintained for a further six days [GFP+ + NaBu] or spontaneously reactivated wells collected at 8 dpi [(GFP+)] and assayed in parallel for infectious virus using Vero cells. Values represent total number of plaque-forming units (pfu) per well and graphed as the mean ± SEM.